Navigation Links
Late-stage ovarian cancer shows promise in two-drug phase I trial
Date:6/9/2010

INDIANAPOLIS -- The combination of decitabine and carboplatin appears to improve the outcome of women who have late-stage ovarian cancer. In an upcoming issue of the journal Cancer (online today), Indiana University researchers report four of 10 patients who participated in a phase I clinical trial had no disease progression after six months of treatment. One patient experienced complete resolution of tumor tissue for a period of time.

Advanced ovarian cancer is often diagnosed too late for treatment to be effective. Patients are often told they have virtually no chance of recovery and only months to live.

Women participating in the study were between 51 and 71, and had previously exhausted all approved treatments for ovarian cancer. They enrolled in an Indiana University Melvin and Bren Simon Cancer Center clinical trial designed to increase their sensitivity to the commonly prescribed ovarian cancer drug, platinum-based carboplatin.

Women with ovarian cancer usually survive less than one year after they become resistant to carboplatin and their cancer recurs, said co-principal investigator Daniela Matei, M.D., an associate professor of medicine at the Indiana University School of Medicine. Matei led the clinical portion of the trial.

"Carboplatin is the most efficient drug therapy for ovarian cancer," Matei said. "Unfortunately, patients with recurrent disease become resistant to the drug after one or two rounds."

Decitabine was first used to treat the study patients intravenously daily for five days followed on the eighth day with carboplatin. After a month, the regimen begins again.

Six months after the trial began, four of the patients had no disease progression. At eight-and-a-half months, seven patients were alive (and at press time, still alive). Cancerous tissue in one of the patients shrank completely.

Adverse reactions to the treatment regiments were mild, including nausea, fatigu
'/>"/>

Contact: Mary L. Hardin
mhardin@iupui.edu
317-274-7722
Indiana University School of Medicine
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Late-stage melanoma results in economic burden
2. Cancer Drug Safe for Late-Stage Pelvic Disease
3. Study Finds Possible Explanation for the Link Between Infertility and Breast/Ovarian Cancer Risks
4. Symptoms have little value for early detection of ovarian cancer
5. Symptoms Alone Dont Spot Ovarian Cancer Early
6. Ultrasound plus proteomic blood analyses may help physicians diagnose early-stage ovarian cancer
7. Abbott Receives European Regulatory Approval for New Ovarian Cancer Diagnostic Test
8. Possible ovarian cancer treatment target identified
9. Arrayit Diagnostics to Bring First Pre-Symptomatic Ovarian Cancer Blood Test to Multi-Billion Dollar Diagnostic Market in 2010
10. Research suggests link between infertility, low egg reserve, and breast/ovarian cancer gene (BRCA1)
11. How to make the best decisions when at high risk for breast or ovarian cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... injuries increase in the summer as people gather around fire ... most vulnerable to these seasonal fire hazards: children. "Young ... by putting their hands on the side of cooking grills," ... Loyola University Medical Center in Maywood, Ill., said in a ... play with fire, you get burned, is true -- ...
(Date:7/12/2014)... “After my mom’s stroke, she loss the use of her ... use of his left side. Eating became a difficult task for ... like them enjoy eating again,” said an inventor, from Fayetteville, N.C. ... HALL PLATE (P C H PLATE). , The PATRICIA CAROL HALL ... eat for individuals who suffer from stroke, experience tremors or loss ...
(Date:7/12/2014)... With prom shopping reaching its final ... is ready to showcase its new and trendy apparels. ... evening dresses in its online shop. Additionally, it is ... these elegant gowns. According to the company’s sales manager, ... 26, 2014. , He says, “Now, worldwide clients ...
(Date:7/12/2014)... “Critical Care Therapeutics in Major Developed ... PCCs and Recombinant Products to Drive Market,” which ... in the US, UK, France, Germany, Italy, Spain, ... of market size for 2013, along with market ... that are being treated using the five major ...
(Date:7/12/2014)... Utah Valley Entrepreneurial Forum Top 25 ... being bestowed to companies in revenue, and pre-revenue startups. ... with recognition for new ideas as well as companies ... , 25 Under 5 highlights outstanding Utah entrepreneurs and ... 5 years old. Award recipients were recognized at their ...
Breaking Medicine News(10 mins):Health News:Burn Injuries More Common in Summer 2Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2
... new funding from the Bill & Melinda Gates Foundation to ... help agency expand services in 11 new countries, ... world,s largest microfinance organizations, today,announced it has received a $24.2 ... will help Opportunity International,s,subsidiary, the Micro Insurance Agency, greatly expand ...
... Quarter 2008 Sees 52 Percent Increase in Sales from Same ... ... Greenway Medical Technologies,Inc., a leading provider of integrated electronic health records ... its second quarter of fiscal 2008, ending,December 31, 2007, were up ...
... announced it will host a webcast and conference call at 10 am,ET on Friday, ... 2007, which ended December 31. Financial,results are scheduled for release after the market closes ... Robert Holster, Chairman and CEO ... Walter Hosp, SVP ...
... more likely to remain depressed than older men, according to ... the February Archives of General Psychiatry. , The Yale ... while depressed than older men, indicating that women live longer ... likelihood of women becoming depressed and remaining depressed, collectively contribute ...
... constructed with soft lithography, should boost research in which ... screen new pharmaceuticals for potential treatment of parasitic infections ... The tools -- an artificial soil device and a ... easily in a human hand -- are detailed in ...
... Alienation Awareness,Organization (PAAO) is beginning the New Year by ... Parental Alienation Awareness Day., Because most people do ... alienation awareness was put forth to help raise,awareness and ... PAAO is to help the public and professionals become,aware ...
Cached Medicine News:Health News:Opportunity International's Micro Insurance Agency to Develop and Provide Life, Health and Crop Insurance for 21 Million Poor People 2Health News:Opportunity International's Micro Insurance Agency to Develop and Provide Life, Health and Crop Insurance for 21 Million Poor People 3Health News:Opportunity International's Micro Insurance Agency to Develop and Provide Life, Health and Crop Insurance for 21 Million Poor People 4Health News:Opportunity International's Micro Insurance Agency to Develop and Provide Life, Health and Crop Insurance for 21 Million Poor People 5Health News:Greenway Medical Technologies Continues Record Setting Growth 2Health News:Greenway Medical Technologies Continues Record Setting Growth 3Health News:Greenway Medical Technologies Continues Record Setting Growth 4Health News:HMS Holdings Corp. Hosts Fourth Quarter and Full Year 2007 Financial Teleconference and Presentation 2Health News:Older women more susceptible to depression than older men 2Health News:New devices to boost nematode research on neurons and drugs 2Health News:New devices to boost nematode research on neurons and drugs 3Health News:Parental Alienation Awareness Organization Begins Preparations for Parental Alienation Awareness Day - April 25th 2
(Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon ... in advanced memory and analog IC solutions, today announced ... Thursday, July 24, 2014, at 7:00 a.m. Pacific Time ... results for the fiscal 2014 third quarter ended June ... via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time ...
(Date:7/10/2014)... WEST JORDAN, Utah , July 10, 2014 /PRNewswire/ ... imaging solutions, and MiE America , Inc., a ... systems, have entered into a long-term agreement naming BC ... in the US. MiE and BC ... a strategic agreement to establish BC Technical as the ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
... , HARRISBURG, Pa., Aug. 20 Department of Environmental ... number of West Nile Virus cases has dropped, the threat still ... and make every effort to control mosquitoes and reduce the threat ... number of West Nile cases has substantially decreased in recent years ...
... , , , , ... Stemedica Cell Technologies , Inc. USA, a ... New Drug (IND) meeting with the U.S. Food and Drug Administration ("FDA") ... mesenchymal bone marrow cells (adult human) as a treatment for ischemic stroke. ...
Cached Medicine Technology:DEP Urges Pennsylvanians to Take Precautions to Reduce West Nile Virus Threat 2DEP Urges Pennsylvanians to Take Precautions to Reduce West Nile Virus Threat 3Stemedica Requests Pre-IND Meeting With FDA 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: